NCT05471674 is a Phase 2 clinical trial of Nivolumab in Hepatocellular Carcinoma, sponsored by Dr Tan-to CHEUNG.

Who is sponsoring NCT05471674?

NCT05471674 is sponsored by Dr Tan-to CHEUNG.

What drugs are being tested in NCT05471674?

Interventions in NCT05471674: Nivolumab, Hepatectomy.

What condition does NCT05471674 study?

NCT05471674 studies Hepatocellular Carcinoma, HCC, Liver Cancer.

Is NCT05471674 still recruiting?

NCT05471674 is currently completed. Last updated 1 February 2023.

Last reviewed 2023-02-01 · How we verify

NCT05471674

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Anti-PD1 in HCC

Completed Phase 2 Last updated 1 February 2023

What this trial tests

Phase 2 trial testing Nivolumab in Hepatocellular Carcinoma in 20 participants. Completed in 31 December 2022.

Timeline

3 July 2020

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Dr Tan-to CHEUNG
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	3 July 2020
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Hong Kong

Drugs / interventions tested

Nivolumab (nivolumab) — full drug profile →
Hepatectomy

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
HCC — all drugs for HCC →
Liver Cancer — all drugs for Liver Cancer →

Sponsor

Dr Tan-to CHEUNG

Who can join

18 and older, any sex, with Hepatocellular Carcinoma or HCC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 2, single-arm trial designed to assess the clinical benefit of treatment with nivolumab administered in patients with untreated, borderline resectable HCC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment.
Hwang SY, Danpanichkul P, Agopian V, Mehta N, et al · · 2025 · cited 96× · PMID 39722614 · DOI 10.3350/cmh.2024.0824
Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC, Ruff SM, Pawlik TM. · · 2024 · cited 16× · PMID 38495884 · DOI 10.3389/fimmu.2024.1355812
Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Intermediate and Locally Advanced Hepatocellular Carcinoma.
Cheung TT, Wai-Hung Ho D, Lyu SX, Zhang Q, et al · · 2024 · cited 13× · PMID 38344450 · DOI 10.1159/000531176
Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art.
Laschtowitz A, Roderburg C, Tacke F, Mohr R. · · 2023 · cited 13× · PMID 36789252 · DOI 10.2147/jhc.s347944
Liver resection and transplantation in the era of checkpoint inhibitors.
Tabrizian P, Marino R, Chow PKH. · · 2024 · cited 7× · PMID 39741696 · DOI 10.1016/j.jhepr.2024.101181
Progress in the treatment of advanced hepatocellular carcinoma with immune combination therapy.
Pan D, Liu HN, Qu PF, Ma X, et al · · 2024 · cited 7× · PMID 38425407 · DOI 10.4251/wjgo.v16.i2.273
Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma.
Kim SJ, Cummins KC, Tsung A. · · 2024 · cited 4× · PMID 38791931 · DOI 10.3390/cancers16101852
Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
Koh B, Tan DJH, Lim WH, Wong JSL, et al · · 2023 · cited 4× · PMID 37284696 · DOI 10.1080/2162402x.2023.2214478

Verify or expand the search:

Other trials of Nivolumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05471674 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr Tan-to CHEUNG
Last refreshed: 1 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05471674.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing